Hyp


Also found in: Dictionary, Thesaurus, Acronyms, Encyclopedia, Wikipedia.

Hyp

Abbreviation for hypoxanthine; hydroxyproline (3Hyp and 4Hyp specifically refer to 3-hydroxyproline and 4-hydroxyproline, respectively).

Hyp

hydroxyproline.
References in periodicals archive ?
Within-subject differences in the frequency and disturbance of the OCD, BDD, HYP, and ED-related mental intrusions
The smallest worthwhile change in number of shuttles completed during the test was 3 shuttles, with CON, NORM, and HYP improving by 10 (7.
One can attributed the significant reduction in liver HYP of TAA rats treated by MOE and/or LDR to the improvement of the oxidative indices and the fibrotic signs.
For example, in the HYP siddhasana refers in its advanced stage to mental steadiness, entrance to sabija samadhi, and so on (1:37-45).
It discusses the successes and challenges HYP experienced in implementing this part of the initiative.
Then the deputy lobes of each group were took out to detect the content of HYP ([micro]g/mg) in concordance with the instruction manual of the kit while the lung homogenates were to measure Col-I content (ng/l) by ELISA.
Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study - Poster 463
The liver coefficient, contents of HYP, serum levels of ALT and AST were all significantly increased in the model group rats.
Results showed that DAC HYP, administered subcutaneously once every four weeks, met the trial's primary endpoint by significantly reducing the annualized relapse rate by 54 percent in the 150 mg dose group (p<0.
The present study included several different forms of AP such as sun-dried (SUN), shade dried (SHD), freeze dried (FDAP), traditional aqueous extract (TRAD), commercially available raw material (RM1, 2 and 3) and six commercially available AP formulations (CP1-6), BSS, STG and STN, HYP and ROP.
The companies said that results showed that DAC HYP, administered subcutaneously once every four weeks, met the trial's primary endpoint by significantly reducing the annualised relapse rate by 54% in the 150 mg dose group (p
Detailed data from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate BG-12 as an oral, monotherapy in people with relapsing-remitting multiple sclerosis (RRMS), and SELECT, a global, registrational Phase 2b clinical trial designed to evaluate DAC HYP in people with RRMS, will be presented at the Congress.